- Trial phase
- Phase 3 / approved-stage (FDA catalyst record 2025-09-30; EU opinion Feb 2026)
- Time to market
- US: already at commercial/approved stage per the FDA catalyst record (2025-09-30). EU: authorisation decision pending after the Feb 2026 opinion. CINDU label expansion still in Phase 3 (study estimated to complete ~2029).
- Why 3/10
- No hard, dated binary is confirmed in the next ~12 months: the US FDA approval catalyst (2025-09-30) and the EMA opinion (2026-02-27) have already passed, and the Phase 3 CINDU readout (est. primary completion 2026-05-22) has no confirmed results date in the data, so this approved, commercial-stage drug, a small part of a mega-cap pipeline, scores in the 3-5 band.
The next potential re-rating events are the CINDU Phase 3 topline (est. primary completion was 2026-05-22; no results posted yet in the data) and the EU authorisation decision that normally follows a CHMP opinion, but neither is a dated binary in hand, so there is no scheduled single-day catalyst to trade. Given Rhapsido's small weight inside Novartis, treat it as pipeline news flow rather than a standalone stock thesis, and re-verify approval/sales claims with external sources once web search is available.
Price Chart
Executive Summary
Rhapsido is the brand name for remibrutinib, a Novartis immunology drug (development code LOU064). SecBot's ingested FDA/EMA/trial records show: a Type 1 new-molecular-entity NDA (218436) recorded as an approval catalyst on 2025-09-30 with a positive ~6% NVS price reaction; an EMA European public assessment report ("Status: Opinion") dated 2026-02-27; a Phase 3 trial in chronic inducible urticaria (est. primary completion 2026-05-22); and a completed Phase 2 peanut-allergy study.
How It Works
An oral small-molecule immunology drug (a new molecular entity per its FDA filing) that dampens a key immune-cell signaling enzyme involved in allergic/hive-type responses, commonly described as a BTK inhibitor, developed as a pill for chronic hives (urticaria) not controlled by antihistamines, rather than an injectable biologic. Note: the mechanism label comes from general drug-class knowledge; the tool results received this session identify the molecule and indications but not the mechanism explicitly.
Trial Status
FDA/OPENFDA records show a Type 1 new-molecular-entity filing (NDA 218436) for remibrutinib dated 2025-09-30, classified by the ingestion pipeline as an approval catalyst; NVS rose about +6.1% (1-day) and +6.7% (5-day) around that date. An EMA EPAR entry for Rhapsido/remibrutinib shows "Status: Opinion" as of 2026-02-27. A Phase 3 trial (NCT05976243, ~362 patients) in chronic inducible urticaria (CINDU) inadequately controlled by H1-antihistamines is active but not recruiting, with estimated primary completion 2026-05-22 and no results posted yet; a Phase 2 peanut-allergy study (NCT05432388) is completed.
The Two-Sided Case
Upcoming Catalysts
- CINDU Phase 3 (NCT05976243) topline results, est. primary completion 2026-05-22, no results posted in the data as of the 2026-03-03 refresh
- EU (EMA/EC) authorisation decision following the 2026-02-27 'Status: Opinion' EPAR
- Potential label-expansion data from the completed Phase 2 peanut-allergy study (NCT05432388)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report